Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
View Patent ↗Devices, systems and methods for compressing, cutting, incising, reconfiguring, remodeling, attaching, repositioning, supporting, dislocating or altering the composition of tissues or anatomical structures to alter their positional or force relationship to other tissues or anatomical structures. In some applications, the invention may be used to used to improve patency or fluid flow through a body lumen or cavity (e.g., to limit constriction of the urethra by an enlarged prostate gland).
1. A method for treating benign prostatic hyperplasia in a subject, said method comprising the steps of:
penetrating with a tethering element, in a direction transverse to a longitudinal axis of the urethra of the subject; and
implanting the tethering element to compress the prostate tissue transverse to the longitudinal axis of the urethra so as to relieve at least some of the constriction in that transverse direction created by the prostate tissue on the urethra as a consequence of the benign prostatic hyperplasia.
2. The method of claim 1 wherein the penetrating step comprises penetrating a capsule of the prostate tissue of the subject.
3. The method of claim 2 further comprising placing an endpiece connected to the tethering element beyond the outer surface of the capsule of the prostate tissue of the subject.
4. The method of claim 1 further comprising attaching a stop to the tethering element on a urethral side of the prostatic tissue of the subject.
5. The method of claim 4 wherein the stop invaginates within the prostatic tissue of the subject.
6. The method of claim 1 further comprising adjusting the length of the tethering element so as to relieve at least some of the constriction in that transverse direction created by the prostate tissue on the urethra as a consequence of the benign prostatic hyperplasia.
7. The method of claim 1 further comprising penetrating, with a penetrating device, in a direction transverse to a longitudinal axis of the subject's urethra, prostate tissue of the subject wherein the penetrating device is configured to be removed from the subject subsequent to the penetrating step.
8. The method of claim 7 wherein the penetrating device carries the tethering element during the penetration step.
9. The method of claim 7 wherein the penetrating device carries the tethering element and an endpiece connected to the tethering element during the penetration step.
10. A method for reducing at least one symptom of benign prostatic hyperplasia said method comprising the steps of:
passing a retaining member and an endpiece through a penetration path created in prostatic tissue of a subject, wherein the retaining member is connected to the endpiece; and
placing the retaining member at least partially within the prostatic tissue of the subject such that at least one symptom of benign prostatic hyperplasia is reduced.
11. The method of claim 10 wherein the penetration path is transverse to a longitudinal axis of the subject's urethra.
12. The method of claim 10 wherein the penetration path extends through a capsule of the prostatic tissue of the subject.
13. The method of claim 10 further comprising placing the endpiece beyond a capsule of the prostatic tissue of the subject.
14. The method of claim 10 further comprising placing a stop on the retaining member such that the stop is closer to a urethral portion of the prostatic tissue than the endpiece.
15. The method of claim 14 wherein placing the stop adjusts the length of the retaining member.
16. The method of claim 10 further comprising creating the penetration path using a penetrating device.
17. The method of claim 16 wherein the penetrating device carries the retaining member.
18. A method for treating benign prostatic hyperplasia in a subject, said method comprising the steps of:
puncturing prostatic tissue of the subject with a puncturing device wherein the puncturing device carries a tissue retainer; and
withdrawing the puncturing device, wherein the tissue retainer remains at least partially within the prostatic tissue and the tissue retainer has a longitudinal axis which is transverse to a longitudinal axis of the subject's urethra subsequent to the withdrawing.
19. The method of claim 18 further comprising puncturing a capsule of the prostate tissue of the subject.
20. The method of claim 19 further comprising placing an endpiece connected to the retaining member outside the capsule of the prostate tissue of the subject.